The VGP released its first 15 high-quality reference genome assemblies today, which are part of the project's first phase to sequence 260 vertebrate genomes.
Using Hi-C, genome sequencing, and optical mapping, researchers profiled structural variants in multiple cancer cell lines, leading to potential non-coding drivers.
The company's offering of 3.36 million units at $6.125 per unit — each consisting of one share of common stock and one warrant — is expected to close Aug. 23.
The company plans to offer nearly 2.5 million units at a price of $6.00 to $7.00 per unit, which at the midpoint of the range would raise about $16 million.
In 2017, Bionano had $9.5 million in revenues and a net loss of 23.4 million, or $7.66 per share.
With its Direct Labeling and Staining (DLS) chemistry, currently available to early-access users, Bionano is pushing forward with more contiguous genome maps.
At PAG, researchers from the Rockefeller University Vertebrate Genome Laboratory outlined sequencing and assembly strategies for phase 1 of the VGP G10K.
After more than two years of development, the British vendor has matched HPC for sequencing alignment accuracy, at far lower power consumption.
The technology could analyze, in one assay, all structural variants known to be diagnostic and prognostic for blood cancers, potentially replacing serial FISH testing.
Increasingly, researchers are combining sequencing, mapping, and scaffolding technologies to generate more contiguous and accurate reference genomes.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.